Therapeutics News and Research

RSS

Researchers identify RGS6 protein that controls both alcohol-seeking behavior and organ damage

What if there was a drug that could simultaneously curb a person's craving for alcohol while also protecting their heart and liver from alcohol's damaging effects?

12 Feb 2015

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.

12 Feb 2015

USF researchers awarded grant to test new drug for age-related hearing loss

A successful treatment for age-related hearing loss (ARHL) is a step closer to reality, thanks to a group of researchers from the University of South Florida. The research team comprised of faculty and students has been awarded $400,000 by Autifony Therapeutics, Ltd, a company based in the United Kingdom, to test a new drug the company developed for ARHL.

12 Feb 2015

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Timing may be decisive when it comes to overcoming cancer's ability to evade treatment. By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models.

12 Feb 2015

Transition Therapeutics commences underwritten public offering of common shares

Transition Therapeutics Inc. announced today that it has commenced an underwritten public offering of its common shares.

12 Feb 2015

Cannabis Science highlights more attendees at the CFA African Healthcare Infrastructure Forum and Brainstorm

Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, highlights additional attendees at the CFA African Healthcare Infrastructure Forum and Brainstorm held at the African Union, in Washington DC, on February 6, 2015.

12 Feb 2015

ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation and Pfizer's Centers for Therapeutic Innovation announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer's disease and related dementias. As part of the first-of-its kind collaboration in Alzheimer's, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer's drug targets.

11 Feb 2015

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian cancer.

11 Feb 2015

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease among men and women in Germany. So-called microsatellite stable colorectal cancer with mutations in the BRAF gene represents a particularly aggressive form.

11 Feb 2015

Researchers generate new reporter system to study bone regeneration potential of embryonic stem cells

A new reporter system used to study the bone regeneration potential of human embryonic stem cells has been generated in research led by the University of Minnesota. The new reporter system is the first of its kind for human pluripotent stem cells and is important for identifying certain agents and pathways that mediate early stages of human bone development.

11 Feb 2015

UNC researchers create new research tool to help crack the histone code

University of North Carolina scientists have created a new research tool, based on the fruit fly, to help crack the histone code. This research tool can be used to better understand the function of histone proteins, which play critical roles in the regulation of gene expression in animals and plants.

11 Feb 2015

Experimental Ebola virus medication shows promise in monkeys

An experimental medication that targets a protein in Ebola virus called VP24 protected 75% of a group of monkeys that were studied from Ebola virus infection, according to new research conducted by the U.S. Army, in collaboration with Sarepta Therapeutics, Inc.

10 Feb 2015

Pfenex, Hospira sign agreement to develop and commercialize LUCENTIS biosimilar

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection).

10 Feb 2015

Excluding cancer survivors from lung cancer clinical trials may not be justified, study finds

The common practice of excluding patients with a prior cancer diagnosis from lung cancer clinical trials may not be justified, according to a study by researchers from UT Southwestern Medical Center.

10 Feb 2015

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration with researchers at Pfizer, has identified a previously unrecognized action of Pfizer's axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia.

10 Feb 2015

Psychedelic drug prevents allergic asthma in mouse model

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.

10 Feb 2015

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.

10 Feb 2015

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").

9 Feb 2015

Preclinical testing of anti-Ebola antibodies can lead to universal flu vaccine

Does the blood of Ebola virus disease survivors contain antibodies and immune cells that could help doctors fight Ebola infections in other people?

9 Feb 2015

New AGA guideline provides guidance to prevent HBV reactivation

Long-term immunosuppressive therapy can cause the hepatitis B virus (HBV) to become active, even in patients who are not aware that they are infected with the virus. A new guideline from the American Gastroenterological Association provides guidance to physicians and patients who use immunosuppressive agents for the treatment of a variety of disorders, including gastrointestinal, dermatologic, neurologic and rheumatologic, among others.

9 Feb 2015

Therapeutics News and Research

Researchers identify RGS6 protein that controls both alcohol-seeking behavior and organ damage

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

USF researchers awarded grant to test new drug for age-related hearing loss

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Transition Therapeutics commences underwritten public offering of common shares

Cannabis Science highlights more attendees at the CFA African Healthcare Infrastructure Forum and Brainstorm

ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Researchers generate new reporter system to study bone regeneration potential of embryonic stem cells

UNC researchers create new research tool to help crack the histone code

Experimental Ebola virus medication shows promise in monkeys

Pfenex, Hospira sign agreement to develop and commercialize LUCENTIS biosimilar

Excluding cancer survivors from lung cancer clinical trials may not be justified, study finds

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Psychedelic drug prevents allergic asthma in mouse model

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Preclinical testing of anti-Ebola antibodies can lead to universal flu vaccine

New AGA guideline provides guidance to prevent HBV reactivation

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News